Get Access to My Next 800% Gain

Had Kevin Hart invested $1.2 million in Jeff Siegel’s top psychedelic stock pick, which is now up nearly 800% — instead of allowing himself to get swindled by a thief — that $1.2 million would now be worth more than $10 million. Had Kevin Hart invested $1.2 million in Jeff Siegel’s top psychedelic stock pick, which is now up nearly 800% — instead of allowing himself to get swindled by a thief — that $1.2 million would now be worth more than $10 million. [Energy and Capital logo] Get Access to My Next 800% Gain [Jeff Siegel Photo] By [Jeff Siegel]( Written Feb 11, 2021 How much is enough? This is a question I often hear from folks who criticize people such as Elon Musk and Jeff Bezos for being incredibly rich. The argument is that at some point, one has so much money that he or she can simply stop hoarding it and share it with others. An honorable endeavor to be sure, but certainly not something that can or should be dictated by others. Some have gone as far as to suggest that a limit should be set on how much money some of these billionaires can make. While I understand the frustration of watching so many people go hungry or so many people struggle to live paycheck to paycheck, it’s absolutely absurd to think you can dictate how much money a person can make — and even more absurd to suggest that we have the right to tell these folks how to spend their own money. I thought about this after reading a Yahoo Finance article this morning about how comedian Kevin Hart got swindled out of $1.2 million by his personal shopper: According to TMZ, the comedian’s personal shopper, Dylan Syer, is accused of defrauding Hart of $1.2 million between October 2017 and February 2019. New York prosecutors say Syer began working for Hart in 2015 and began building the actor’s trust through authorized purchases; however, as the years went by, Syer allegedly began using Hart’s credit card to pour money into his own account. I don’t know what it’s like to have a personal shopper. And even if I had Kevin Hart's money (his net worth clocks in at around $200 million), I still wouldn’t pay someone to buy my clothes. But that doesn’t mean I have any right to tell Kevin Hart whether or not he should use HIS money to hire a personal shopper. Did This $3 Firm Just Make Tesla Obsolete? There will be 12 million electric cars on the road in five years. And believe it or not, [THIS]( strange liquid could power every single one. [gcs nene liquid]( Don't believe it? See the proof for yourself... [Click here.]( My point is this... Just because someone is wealthy doesn’t mean he or she has to abide by the wishes and demands of those who aren’t rich. That being said, thinking about Kevin Hart’s situation, I can’t stop myself from thinking about how, had he invested that $1.2 million in my top psychedelic stock pick, which is now up nearly 800% — instead of allowing himself to get swindled by a thief — that $1.2 million would now be worth more than $10 million. Let me explain… If you’re a regular reader of these pages, you know that I’ve been very bullish on the psychedelics space for the past two years — and for good reason. Psychedelic medicines represent the next evolution in treatments for mental illness, brain trauma, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. I say this because I’ve spent the past two years poring through the research and interviewing the experts. And what I’m seeing is truly game-changing because current treatments on the market for all of these ailments are either highly ineffective or don’t work at all. This is why the FDA has given breakthrough therapy status to a number of companies developing psychedelic medicines for a variety of brain-related diseases. If you’re unfamiliar, breakthrough therapy status essentially allows the FDA to expedite clinical trials so it can get these medicines to market much faster. It’s an incredibly bullish indicator for biotech and pharma investors, to be sure. New Year, New Opportunities Thanks to a landmark act of Congress, everyday investors like yourself can now access this “private market” that was once off-limits to those under a certain net worth. This private market hands out as much as $214 billion in profits every year, and now you can take your slice of the pie. And here’s the kicker: It’s growing 10 times faster than the stock market! I’ve spent months researching and digging to get you all the details and opportunities, and it’s finally ready for you to see. Inside this free report, I discuss how you can unlock the secrets of private-market investing and make them work to your advantage. But that’s not all... You will also have the opportunity to join us in these private companies that could deliver double, triple, and even quadruple the returns. [Click here now to learn how to access your free report...]( Now, to give you an idea of the size of the potential market value for psychedelics, here’s a short list of illnesses and diseases that many believe can be treated — or even cured — using psychedelic medicines: - Global market for depression and anxiety treatments: $19 billion by 2027 - Global market for drug addiction treatments: $31 billion by 2027 - Global market for traumatic brain injury treatments: $156 billion by 2024 - Global market for neurodegenerative diseases drugs: $62.7 billion by 2026 - Global market for ADHD treatments: $24.9 billion by 2025 - Global market for bipolar disorder treatments: $4.9 billion by 2025 - Global market for schizophrenia drugs: $7.9 billion by 2022 Combined, you’re looking at more than $300 million up for grabs. That ain’t chump change, and that’s why I continue to invest — and profit handsomely — from the psychedelics market. You should be doing the same. And that’s why I put together this [“Introduction to Psychedelics”]( report, so you can learn more about this space, as well as some of the companies that are absolutely crushing it. Of course, if you’re already a billionaire and would rather spend your cash on personal shoppers and a fleet of yachts, I get it. Certainly, if I had Jeff Bezos’ scratch, I’d be swinging in a hammock in Hawaii right now, eating mangoes and playing my guitar. But for most of us, that’s simply not an option. But what is an option is getting a piece of a market that is already shaping up to be the most lucrative of 2021. [Click here now to get started.]( To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel --------------------------------------------------------------- This Medical Breakthrough Could Make You up To $300,000 Did you know that Alzheimer’s is the sixth-leading cause of death in America? We’re so focused on beating COVID-19 that sometimes we forget other deadly diseases exist... But that’s why right now couldn't be a better time to invest in biotech. This pandemic has made every illness the #1 enemy. And that means early investors could make an absolute killing in the “right” biotech companies. What I’ve found is a company that could turn a small sum into as much as $300,000. It’s already been granted breakthrough status by the FDA, and clinical trials are being conducted as we speak. Science Magazine calls it the “most important discovery in half a century.” And maybe only 1% of investors know about this breakthrough. We’re talking about diabetes… depression… substance addiction… PTSD… and many more potentially just vanishing from the body. [Click here for all the details…]( Browse Our Archives [The Most Misunderstood Investment in the U.S. (and It’s Not Bitcoin)]( [5G-Volta and What Could Be 2021's Most Explosive Stock]( [Marshalls and Ross Have Outperformed Walmart and Target]( [26 Million Americans Are Asking Themselves This One Question]( [The Most Unexpected Rally in 2021 Will Be Oil]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2021, [Angel Publishing LLC](. All rights reserved. 3 E Read Street, Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.